Opinion The case for routine patient review in long COVID research, 2026, Soares et al

rvallee

Administrator
Staff member
The case for routine patient review in long COVID research
Signup-walled: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00134-9/abstract
(As in it says you can simply sign in with a Lancet account and read it)

Long COVID is an infection-associated chronic condition that occurs after SARS-CoV-2 infection and can lead to sometimes severe disability.1–3 In early 2024, long COVID had already affected 400 million people, with an estimated annual global economic impact of US$1 trillion.2 6 years into the COVID-19 pandemic, research into long COVID has progressed considerably, and evidence implicates several pathomechanisms, including aberrant immunity, persistent pathogens, endothelial dysfunction, and mitochondrial dysfunction.1–3 People with long COVID have played a crucial role in the field's development, establishing long COVID as a disease entity in the scientific literature4,5 and publishing numerous articles on epidemiology, public health, pathomechanisms, and trial design—two of which are among the ten most cited in the field.1,5
 
Back
Top Bottom